Roth Capital Brokers Raise Earnings Estimates for Helius Medical Technologies, Inc. (NASDAQ:HSDT)
Helius Medical Technologies, Inc. (NASDAQ:HSDT – Free Report) – Analysts at Roth Capital upped their Q1 2024 earnings per share (EPS) estimates for shares of Helius Medical Technologies in a research note issued on Sunday, March 31st. Roth Capital analyst J. Aschoff now expects that the company will post earnings of ($2.70) per share for the quarter, up from their prior forecast of ($3.27). The consensus estimate for Helius Medical Technologies’ current full-year earnings is ($8.05) per share. Roth Capital also issued estimates for Helius Medical Technologies’ Q2 2024 earnings at ($2.04) EPS, Q3 2024 earnings at ($2.03) EPS, Q4 2024 earnings at ($1.92) EPS, FY2024 earnings at ($8.58) EPS, FY2025 earnings at ($2.06) EPS, FY2026 earnings at $2.29 EPS, FY2027 earnings at $9.21 EPS and FY2028 earnings at $14.88 EPS.
Separately, Roth Mkm increased their price objective on Helius Medical Technologies to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, March 5th.
View Our Latest Stock Analysis on HSDT
Helius Medical Technologies Stock Up 14.5 %
Shares of NASDAQ HSDT opened at $6.48 on Wednesday. The stock has a market cap of $5.77 million, a PE ratio of -0.45 and a beta of 1.44. Helius Medical Technologies has a 52-week low of $4.29 and a 52-week high of $14.44. The business has a 50-day moving average price of $5.96 and a 200 day moving average price of $6.98.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. acquired a new position in Helius Medical Technologies in the third quarter valued at approximately $108,000. Renaissance Technologies LLC lifted its position in Helius Medical Technologies by 2,047.2% in the second quarter. Renaissance Technologies LLC now owns 227,600 shares of the company’s stock worth $44,000 after purchasing an additional 217,000 shares during the period. Finally, BlackRock Inc. lifted its position in Helius Medical Technologies by 8,297.9% in the third quarter. BlackRock Inc. now owns 255,381 shares of the company’s stock worth $71,000 after purchasing an additional 252,340 shares during the period. Institutional investors and hedge funds own 18.63% of the company’s stock.
About Helius Medical Technologies
Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company’s product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.
See Also
Receive News & Ratings for Helius Medical Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Helius Medical Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.
